vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $30.1M, roughly 1.6× Dominari Holdings Inc.). IRONWOOD PHARMACEUTICALS INC runs the higher net margin — -4.8% vs -438.1%, a 433.3% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs -47.3%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
DOMH vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $47.7M |
| Net Profit | $-131.8M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | -8.9% | 14.3% |
| Net Margin | -438.1% | -4.8% |
| Revenue YoY | 220.4% | -47.3% |
| Net Profit YoY | -12426.2% | -200.9% |
| EPS (diluted) | $-6.94 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $47.7M | ||
| Q3 25 | $50.8M | $122.1M | ||
| Q2 25 | $34.1M | $85.2M | ||
| Q1 25 | $8.1M | $41.1M | ||
| Q4 24 | $9.4M | $90.5M | ||
| Q3 24 | $4.0M | $91.6M | ||
| Q2 24 | $6.2M | $94.4M | ||
| Q1 24 | $1.4M | $74.9M |
| Q4 25 | $-131.8M | $-2.3M | ||
| Q3 25 | $125.2M | $40.1M | ||
| Q2 25 | $16.6M | $23.6M | ||
| Q1 25 | $-32.5M | $-37.4M | ||
| Q4 24 | $1.1M | $2.3M | ||
| Q3 24 | $-4.2M | $3.6M | ||
| Q2 24 | $-6.1M | $-860.0K | ||
| Q1 24 | $-5.4M | $-4.2M |
| Q4 25 | -8.9% | 14.3% | ||
| Q3 25 | -3.1% | 61.8% | ||
| Q2 25 | -57.0% | 53.2% | ||
| Q1 25 | -394.6% | -70.7% | ||
| Q4 24 | 0.4% | 34.8% | ||
| Q3 24 | -79.1% | 28.0% | ||
| Q2 24 | -44.3% | 26.5% | ||
| Q1 24 | -205.2% | 14.7% |
| Q4 25 | -438.1% | -4.8% | ||
| Q3 25 | 246.4% | 32.8% | ||
| Q2 25 | 48.7% | 27.7% | ||
| Q1 25 | -400.5% | -90.9% | ||
| Q4 24 | 11.4% | 2.5% | ||
| Q3 24 | -104.2% | 4.0% | ||
| Q2 24 | -99.1% | -0.9% | ||
| Q1 24 | -398.0% | -5.6% |
| Q4 25 | $-6.94 | $0.01 | ||
| Q3 25 | $7.27 | $0.23 | ||
| Q2 25 | $1.12 | $0.14 | ||
| Q1 25 | $-3.02 | $-0.23 | ||
| Q4 24 | $0.21 | $0.03 | ||
| Q3 24 | $-0.67 | $0.02 | ||
| Q2 24 | $-1.01 | $-0.01 | ||
| Q1 24 | $-0.91 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $-261.8M |
| Total Assets | $112.9M | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $215.5M | ||
| Q3 25 | $176.2M | $140.4M | ||
| Q2 25 | $28.2M | $92.9M | ||
| Q1 25 | $18.9M | $108.5M | ||
| Q4 24 | $8.2M | $88.6M | ||
| Q3 24 | $7.2M | $88.2M | ||
| Q2 24 | $12.1M | $105.5M | ||
| Q1 24 | $7.1M | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | $69.4M | $-261.8M | ||
| Q3 25 | $210.2M | $-264.2M | ||
| Q2 25 | $88.6M | $-308.2M | ||
| Q1 25 | $42.4M | $-334.1M | ||
| Q4 24 | $39.9M | $-301.3M | ||
| Q3 24 | $38.3M | $-311.3M | ||
| Q2 24 | $42.4M | $-321.7M | ||
| Q1 24 | $47.7M | $-330.5M |
| Q4 25 | $112.9M | $396.9M | ||
| Q3 25 | $223.4M | $396.1M | ||
| Q2 25 | $109.3M | $342.9M | ||
| Q1 25 | $52.3M | $327.2M | ||
| Q4 24 | $47.1M | $350.9M | ||
| Q3 24 | $43.4M | $389.5M | ||
| Q2 24 | $49.1M | $395.6M | ||
| Q1 24 | $52.2M | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $74.6M |
| Free Cash FlowOCF − Capex | — | $74.6M |
| FCF MarginFCF / Revenue | — | 156.3% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $74.6M | ||
| Q3 25 | $-4.9M | $47.6M | ||
| Q2 25 | $-353.0K | $-15.1M | ||
| Q1 25 | $1.2M | $20.0M | ||
| Q4 24 | $-16.7M | $15.2M | ||
| Q3 24 | $-4.7M | $9.9M | ||
| Q2 24 | $1.4M | $33.5M | ||
| Q1 24 | $-8.6M | $45.0M |
| Q4 25 | — | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $-15.1M | ||
| Q1 25 | — | $19.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.4M | ||
| Q1 24 | — | $44.9M |
| Q4 25 | — | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | -17.7% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 35.4% | ||
| Q1 24 | — | 60.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | 1.19× | ||
| Q2 25 | -0.02× | -0.64× | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | 6.74× | ||
| Q3 24 | — | 2.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
IRWD
Segment breakdown not available.
